RECORDATI

Recordati has acquired exclusive licensing and supply rights to commercialize Vazkepa (icosapent ethyl) across 59 European countries in a deal worth up to $175 million with Amarin.

Novo Nordisk's 25 mg oral semaglutide for chronic weight management received FDA acceptance in May 2025, potentially becoming the first oral GLP-1 therapy approved for obesity treatment.

The FDA has approved an expanded indication for osilodrostat (Isturisa) to treat endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

• Clinical trial sponsors and CROs must establish optimal oversight balance, with experts warning that both excessive and insufficient monitoring can impede trial success and efficiency. • Industry leaders at Veeva's Clinical Operations Outsourcing 2024 Forum stress the importance of early collaboration agreements and transparent communication between sponsors and CROs. • As clinical trials become increasingly complex, particularly in specialized therapies, the need for efficient sponsor oversight becomes more crucial for ensuring trial quality and regulatory compliance.

Recordati has secured worldwide rights to Enjaymo, the first and only approved treatment for cold agglutinin disease (CAD), from Sanofi for an upfront payment of $825 million with potential milestone payments of $250 million.

South Korea is implementing reforms to reduce drug reimbursement times from approximately 4 years to align more closely with other advanced nations like the US, Japan, and Germany.

Italy's pharmaceutical market is projected to decline from $25.1 billion in 2012 to $23.5 billion by 2020, driven by government austerity measures and strict drug pricing policies.